Shots:
- Innate Pharma & Sobi have entered into a strategic partnership to initiate P-III (TELLOMAK-3) trial of lacutamab in CTCL, supporting a planned accelerated approval filing in Sézary syndrome
- TELLOMAK-3 is expected to support full approval filings in Sézary syndrome & mycosis fungoides. Sobi will gain exclusive global commercialization rights upon potential accelerated approval & may assume full global development rights following positive P-III results
- Innate will receive $75M upfront, ~$40M in near-term Sézary syndrome development milestones, and ~$465M tied to Sobi’s option for full development rights plus future regulatory/commercial milestones, along with tiered double-digit royalties on net sales
Ref: Businesswire | Image: Innate Pharma & Sobi | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
